Where did you get your information because it contradicts the press release from June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis.
Also, my favorite part: In addition, non-invasive tests as secondary endpoints will be conducted at the beginning, middle and end of the study."
Also, screening for FX was supposed to start in August so it very well may have already
Market Data 
Markets 
